NGM craters after dropping mid-stage NASH candidate aldaferminShares in NGM Biopharma have plummeted after the US biotech said it would abandon development of aldafermin in Share XNGM craters after dropping mid-stage NASH candidate aldaferminhttps://pharmaphorum.com/news/ngm-craters-after-dropping-mid-stage-nash-candidate-aldafermin/
